Year archive

BerGenBio — 2017 filings

All 85 regulatory filings released by BerGenBio (BGBIO) in 2017, sourced directly from the official regulator.

85 Filings

2017 Period

2017 filings (85)

Filing	Released	Lang
Financial calendar Report Publication Announcement	2017-12-21	English
BerGenBio ASA: Share capital increase Share Issue/Capital Change	2017-12-14	Norwegian
BerGenBio ASA: Share capital increase Share Issue/Capital Change	2017-12-14	English
BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB's 8th Annual Nordic Healthcare Conference Earnings Release FY 2017	2017-12-14	English
BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB's 8th Annual Nordic Healthcare Conference Investor Presentation	2017-12-14	English
BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB's 8th Annual Nordic Healthcare Conference Earnings Release FY 2017	2017-12-14	English
BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting Regulatory Filings	2017-12-11	English
BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting Regulatory Filings	2017-12-11	English
BerGenBio - US Clinical Trial Update Legal Proceedings Report	2017-11-27	English
BerGenBio - US Clinical Trial Update Legal Proceedings Report	2017-11-27	English
BerGenBio ASA: Exercise of employee share options and increase of capital Share Issue/Capital Change	2017-11-17	English
BerGenBio ASA: Exercise of employee share options and increase of capital Share Issue/Capital Change	2017-11-17	English
BerGenBio ASA: Results for the Third Quarter 2017 Interim / Quarterly Report Q3 2017	2017-11-17	English
BerGenBio ASA: Results for the Third Quarter 2017 Interim / Quarterly Report Q3 2017	2017-11-17	English
BerGenBio ASA: Results for the Third Quarter 2017 Investor Presentation	2017-11-17	English
BerGenBio ASA: Results for the Third Quarter 2017 Earnings Release Q3 2017	2017-11-17	English
BerGenBio to present at Jefferies 2017 London Healthcare Conference Regulatory Filings	2017-11-16	English
BerGenBio to present at Jefferies 2017 London Healthcare Conference Report Publication Announcement	2017-11-16	English
BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium Regulatory Filings	2017-11-14	English
BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium Regulatory Filings	2017-11-14	English
BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast Report Publication Announcement	2017-11-10	Norwegian
BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast Report Publication Announcement	2017-11-10	English
Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting Regulatory Filings	2017-11-01	English
Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting Regulatory Filings	2017-11-01	English
BerGenBio Announces Start of Ph II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA® for Patients with Advanced Lung Cancer Regulatory Filings	2017-10-24	English
BerGenBio Announces Start of Ph II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA® for Patients with Advanced Lung Cancer Regulatory Filings	2017-10-24	English
BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer Regulatory Filings	2017-10-19	English
BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer Regulatory Filings	2017-10-19	Norwegian
BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma Regulatory Filings	2017-10-18	English
BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma Regulatory Filings	2017-10-18	English
BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma Investor Presentation	2017-10-18	Norwegian
BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama Investor Presentation	2017-10-16	English
Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma Regulatory Filings	2017-10-16	Norwegian
BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama Regulatory Filings	2017-10-16	English
Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma Investor Presentation	2017-10-16	Norwegian
Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma Regulatory Filings	2017-10-12	English
Klinisk studie med BGB324, BerGenBio's selektive First-in-Class AXL Inhibitor, presenteres på 9th World Congress of Melanoma Regulatory Filings	2017-10-12	Norwegian
Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma Regulatory Filings	2017-10-12	English
Klinisk studie med BGB324, BerGenBio's selektive First-in-Class AXL Inhibitor, presenteres på 9th World Congress of Melanoma Regulatory Filings	2017-10-12	Norwegian
BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer Environmental & Social Information	2017-09-28	English
BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer Regulatory Filings	2017-09-28	English
BerGenBio ASA: Results for the Second Quarter and Half year 2017 Earnings Release H1 2017	2017-08-18	English
BerGenBio ASA: Results for the Second Quarter and Half year 2017 Interim / Quarterly Report H1 2017	2017-08-18	English
BerGenBio ASA: Results for the Second Quarter and Half year 2017 Investor Presentation	2017-08-18	English
BerGenBio ASA: Results for the Second Quarter and Half year 2017 Earnings Release Q2 2017	2017-08-18	English
BerGenBio ASA: Invitation to Second Quarter and Half year 2017 Results Presentation and Webcast Report Publication Announcement	2017-08-11	English
BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston Regulatory Filings	2017-07-26	English
BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston Regulatory Filings	2017-07-26	English
BerGenBio ASA: Share capital increase registered Share Issue/Capital Change	2017-07-13	Norwegian
BerGenBio ASA: Share capital increase registered Share Issue/Capital Change	2017-07-13	English
BerGenBio ASA: Exercise of employee share options and increase of share capital Share Issue/Capital Change	2017-06-27	English
BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA® for Advanced Lung Cancer Environmental & Social Information	2017-06-26	English
BerGenBio's selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 Investor Presentation	2017-06-06	English
BerGenBio's selective first-in-class Axl inhibitor, BGB324, Featured in a Poster Presentation at ASCO Annual Meeting 2017 Regulatory Filings	2017-06-06	English
BerGenBio ASA: Results for the First Quarter 2017 Earnings Release Q1 2017	2017-05-23	English
BerGenBio ASA: Results for the First Quarter 2017 Interim / Quarterly Report Q1 2017	2017-05-23	English
BerGenBio ASA: Results for the First Quarter 2017 Investor Presentation	2017-05-23	English
BerGenBio ASA: Results for the First Quarter 2017 Earnings Release Q1 2017	2017-05-23	English
BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma Regulatory Filings	2017-05-22	English
Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017 Regulatory Filings	2017-05-19	English
BerGenBio ASA: First Quarter 2017 Results Presentation and Webcast Report Publication Announcement	2017-05-16	English
BerGenBio ASA - Stabilisation notice Share Issue/Capital Change	2017-05-08	English
Oslo Børs - BerGenBio ASA - New security will be listed 07.04.2017 Delisting Announcement	2017-04-07	English
BerGenBio ASA - Stabilisation and over-allotment notice Share Issue/Capital Change	2017-04-07	English
Financial calendar Report Publication Announcement	2017-04-06	English
Oslo Børs - BerGenBio ASA - New security is quoted as from 07.04.2017 Report Publication Announcement	2017-04-06	English
BerGenBio ASA - INCREASE IN SHARE CAPITAL Capital/Financing Update	2017-04-06	English
Flagging BerGenBio Declaration of Voting Results & Voting Rights Announcements	2017-04-06	Norwegian
BerGenBio ASA - Allocation to primary insiders Share Issue/Capital Change	2017-04-06	English
BerGenBio ASA - Successful completion of initial public offering Capital/Financing Update	2017-04-06	English
BerGenBio ASA - Last day of application period Report Publication Announcement	2017-04-05	English
BerGenBio ASA - APPLICATIONS BY PRIMARY INSIDERS Director's Dealing	2017-04-03	English
BerGenBio's first-in-class Axl inhibitor, BGB324, featured in two immuno-oncology presentations at AACR Annual Meeting Regulatory Filings	2017-04-03	English
The Board of Oslo Børs approves BerGenBio ASA for listing on Oslo Børs Regulatory Filings	2017-03-31	English
Styret ved Oslo Børs godkjenner BerGenBio ASA for notering på Oslo Børs Regulatory Filings	2017-03-31	Norwegian
BerGenBio ASA - Update on bookbuilding Share Issue/Capital Change	2017-03-31	English
BerGenBio ASA - APPLICATIONS BY PRIMARY INSIDERS Director's Dealing	2017-03-30	English
Received application for listing - BerGenBio ASA Report Publication Announcement	2017-03-29	English
Mottatt søknad om notering - BerGenBio ASA Delisting Announcement	2017-03-29	Norwegian
BerGenBio ASA - Publication of prospectus and commencement of the application period Capital/Financing Update	2017-03-29	English
Mottatt søknad om notering - BerGenBio ASA Report Publication Announcement	2017-03-28	Norwegian
Received application for listing - BerGenBio ASA Regulatory Filings	2017-03-28	English
BerGenBio announces the terms of its Initial Public Offering Capital/Financing Update	2017-03-28	English
BerGenBio announces its intention to launch an Initial Public Offering and apply for a listing on Oslo Børs Regulatory Filings	2017-03-08	English
BerGenBio enters collaboration with MSD focused on clinical evaluation of BGB324 in combination with KEYTRUDA® (pembrolizumab) in advanced lung and breast cancer Regulatory Filings	2017-03-08	English

Filings by year

2025 34 filings
2024 62 filings
2023 120 filings
2022 91 filings
2021 175 filings
2020 213 filings
2019 81 filings
2018 100 filings
2017 85 filings